Substance P-Guided Peptide Vectors Deliver Gene Therapy Specifically to Brain Tumor Cells | Research

The takeaway

A peptide-based delivery system using substance P achieved targeted gene delivery to glioma cells by exploiting the NK1 receptor, crossing the blood-brain barrier in both lab and zebrafish models.

36% higher glioma targeting
The substance P-containing peptide vector transfected glioma cells 36% more efficiently than normal cells by exploiting NK1 receptor expression

What the researchers found

Peptide vector P-02 (SP-PEG4-K(C18)-(LLHH)3-R9) achieved 36% higher transfection in glioma U87 cells versus normal 293T cells, with NK1 receptor-mediated targeting confirmed. The vector crossed a BBB model in vitro and achieved gene expression in zebrafish brain.

Why it matters

Glioblastoma is the deadliest brain cancer with few effective treatments. A peptide delivery system that can both cross the blood-brain barrier and selectively target tumor cells could make gene therapy a viable treatment option.

The numbers in context

36% higher transfection ratio in U87 vs 293T; NK1R-mediated; BBB model crossed; EGFP expression in zebrafish brain

How the study worked

In vitro and zebrafish study. Peptide vectors with substance P targeting, cell-penetrating, and endosomal escape segments were synthesized. Gene transfection tested in U87 glioma, 293T-NK1R, and normal 293T cells. BBB crossing assessed in vitro and in zebrafish.

Who was studied

U87 glioma cells, 293T cells, and zebrafish

What this study cannot tell us

Preclinical only — in vitro cell lines and zebrafish model. No mammalian in vivo data. Transfection efficiency compared to established methods remains modest. Long-term safety, immune response, and therapeutic gene payload effects not assessed.

How to read the evidence

Low evidence grade: in vitro cell culture and zebrafish model only. No mammalian in vivo data or therapeutic outcome measures.

When this study was published

Published in 2021. Peptide-based gene delivery for brain tumors remains an active but early-stage research area.

The bigger picture

Peptide-based gene delivery vectors are an emerging alternative to viral vectors, offering better safety profiles and customizable targeting. Using neuropeptides like substance P for tumor targeting represents a growing strategy in precision oncology for brain cancers.

Questions still open

Can this substance P-guided vector deliver therapeutic genes that actually shrink glioblastoma tumors in mammalian models?
How does this peptide vector compare to viral gene delivery systems in terms of efficiency and safety?
Could the NK1 receptor targeting approach be adapted for other cancers that overexpress this receptor?

Common questions

What is substance P and why use it for brain tumor targeting?

Substance P is a natural neuropeptide involved in pain signaling. Glioma brain tumor cells overexpress its receptor (NK1R), so attaching substance P to a delivery vehicle lets it find and enter tumor cells preferentially.

How close is this to being a real treatment?

This is early-stage research. The concept works in cell cultures and zebrafish, but would need extensive testing in mammalian models and eventually human clinical trials before becoming a treatment.

Read the original research

Substance P containing peptide gene delivery vectors for specifically transfecting glioma cells mediated by a neurokinin-1 receptor.

Journal of materials chemistry. B, 9(32), 6347-6356

View on PubMed ↗Publisher’s paper ↗

Citation

Ding, Guihua; Wang, Taoran; Han, Zhenbin; Tian, Long; Cheng, Qin; Luo, Longlong; Zhao, Baoquan; Wang, Chenhong; Feng, Siliang; Wang, Lianshuai; Meng, Zhao; Meng, Qingbin. (2021). Substance P containing peptide gene delivery vectors for specifically transfecting glioma cells mediated by a neurokinin-1 receptor.. Journal of materials chemistry. B, 9(32), 6347-6356. https://doi.org/10.1039/d1tb00577d